venetoclax,rituximab,pirtobrutinib
eli lilly,abbvie,roche
['bruin', 'mantle,(-dismantle)', 'lymphoma', 'lymsm', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'loxo', 'valent ,(-prevalent)']
updated results &amp; subgroup analysis w/ 2yrs of survival follow-up from the phase 1/2 bruin study, investigating a non-covalent (reversible) #btki in patients w/ mantle cell #lymphoma previously treated w/ a covalent btki. #lymsm presented at #asco23: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK